Formulations of a compound modulating kinases

1. A method for treating a subject suffering from a disease or condition mediated by a protein kinase selected from c-fms, c-kit, Flt3, or combination thereof, or mediated by macrophages or microglia, comprising administering to the subject a therapeutically effective amount of a composition comprising: 40% to 60% W/W of Compound I having the following structure:

and wherein Compound I is a crystalline HCl salt characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 7.3, 23.3 and 28.2°2θ as determined on a diffractometer using Cu-Kα radiation; 20% to 35% W/W of a poloxamer; 10% to 22% W/W of an excipient; 1% to 5% W/W of a disintegrant; and 0.5% to 3% W/W of a lubricant;

and wherein the disease or condition is selected from osteoporosis, neurofibromatosis, Alzheimer's disease, progressive supranuclear palsy, epilepsy, brain trauma, tauopathies, non-small cell lung cancer, anterior eye disease, posterior eye disease, lysosomal storage disease, multiple sclerosis, neuro-inflammation, neuroinflammatory disorders, complex regional pain syndrome, binswager type dementia, dementia with lewy bodies, vascular dementias, multi infarct dementia, pseudo-dementia, HIV, cerebral palsy, glaucoma, bladder cancer, ovarian cancer, prostate cancer, pancreatic cancer, colorectal cancer, acute myeloid leukemia, monocytic leukemia, breast cancer, cholangiocarcinoma, endometrial cancer, esophageal cancer, glioma, glioblastoma, giant cell tumors, hepatocellular carcinoma, Hodgkin lymphoma, melanoma, mesothelioma, renal cell carcinoma, malignant peripheral nerve sheath tumors (MPNST), plexiform neurofibromas, salivary gland tumors, gastrointestinal stromal tumors (GIST), pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), giant cell tumors of the tendon sheath (GCT-TS), and catatonia.

2. The method of claim 1 , wherein the poloxamer is poloxamer 407.

3. The method of claim 1 , wherein the diffractogram further comprises peaks at 16.6 and 20.9°2θ±0.2°.

4. The method of claim 1 , wherein Compound I is characterized by:

i) a diffractogram substantially as shown in FIG. 1 ;

ii) a differential scanning calorimetry (DSC) thermogram comprising an endotherm at 234° C.;

iii) a DSC thermogram substantially as shown in FIG. 2 ;

iv) thermogravimetric analysis (TGA) comprising a thermogram substantially as shown in FIG. 3 ; or

v) a dynamic vapor sorption (DVS) curve substantially as shown in FIG. 4 .

5. The method of claim 1 , wherein the composition comprises 45% to 55% W/W of Compound I; 24% to 32% W/W of the poloxamer; 14% to 20% W/W of the excipient; 2% to 4% W/W of the disintegrant; and 1.0% to 2.5% W/W of the lubricant.

6. The method of claim 1 , wherein the composition comprises 48% to 53% W/W of Compound I; 26% to 29% W/W of the poloxamer; 15% to 18% W/W of the excipient; 2.5% to 3.5% W/W of the disintegrant; and 1.2% to 1.8% W/W of the lubricant.

7. The method of claim 1 , wherein the composition comprises 51.2% (±3%) W/W of Compound I; 27.6% (±3%) W/W of the poloxamer; 16.8% (±3%) W/W of the excipient; 3% (±1%) W/W of the disintegrant; and 1.5% (±1%) W/W of the lubricant.

8. The method of claim 1 , wherein the excipient is mannitol; the disintegrant is crospovidone; and the lubricant is magnesium stearate.

9. The method of claim 1 , wherein the poloxamer is poloxamer 407; the excipient is mannitol; the disintegrant is crospovidone; and the lubricant is magnesium stearate.

10. The method of claim 9 , wherein the composition comprises 45% to 55% W/W of Compound I; 24% to 32% W/W of poloxamer 407; 14% to 20% W/W of mannitol; 2% to 4% W/W of crospovidone; and 1.0% to 2.5% W/W of magnesium stearate.

11. The method of claim 9 , wherein the composition comprises 48% to 53% W/W of Compound I; 26% to 29% W/W of poloxamer 407; 15% to 18% W/W of mannitol; 2.5% to 3.5% W/W of crospovidone; and 1.2% to 1.8% W/W of magnesium stearate.

12. The method of claim 9 , wherein the composition comprises 51.2% W/W (±3%) of Compound I; 27.6% (±3%) W/W of poloxamer 407; 16.8% (±3%) W/W of mannitol; 3% W/W (±1%) of crospovidone; and 1.5% (±1%) W/W of magnesium stearate.

13. The method of claim 1 , wherein the composition is in a capsule form suitable for oral dosage.

14. The method of claim 13 , wherein the capsule comprises hard gelatin or hypromellose.

15. The method of claim 14 , wherein the capsule comprises hypromellose.

16. The method of claim 1 , said method further comprising administering to the subject a PD-L1 inhibitor, a PD-1 inhibitor, an IDO inhibitor, a monoclonal antibody, or a FLT3 kinase inhibitor.

17. The method of claim 1 , wherein the disease or condition is plexiform neurofibromas.

18. The method of claim 1 , wherein the disease or condition is tenosynovial giant cell tumor.

19. The method of claim 1 , wherein the disease or condition is pigmented villonodular synovitis.

20. The method of claim 1 , wherein the disease or condition is malignant peripheral nerve sheath tumors.

21. The method of claim 1 , wherein the disease or condition is ovarian cancer.

22. The method of claim 1 , wherein the disease or condition is pancreatic cancer.

23. The method of claim 1 , wherein the disease or condition is colorectal cancer.

24. The method according to claim 22 , further comprising administering a therapeutically effective amount of a PD-L1 inhibitor.

25. The method according to claim 24 , wherein the PD-L1 inhibitor is durvalumab.

26. The method according to claim 23 , further comprising administering a therapeutically effective amount of a PD-L1 inhibitor.

27. The method according to claim 26 , wherein the PD-L1 inhibitor is durvalumab.

28. The method of claim 1 , wherein the disease or condition is neurofibromatosis.

29. The method of claim 1 , wherein the disease or condition is gastrointestinal stromal tumors.

30. The method of claim 1 , wherein the disease or condition is Alzheimer's disease.